Upcoming · By Invitation

International Translational Oncology Exchange

Boston · May 13, 202614:00 – 16:00 ET
Learn more →
←Back to Expert Scholars
research / researchNK cells and tumor immune evasion

Mark J. Smyth

马克·史密斯

PhD, FAA

🏢QIMR Berghofer Medical Research Institute(昆士兰医学研究所伯格霍费尔医学研究院)🌐Australia

Laboratory Head, Immunology of Cancer and Infection癌症与感染免疫学实验室主任

82
h-index
2
Key Papers
3
Awards
2
Key Contributions

👥Biography 个人简介

Mark Smyth is a leading cancer immunologist who has made foundational contributions to understanding how natural killer cells mediate tumor immune surveillance and how tumors evade NK cell recognition. His laboratory discovered that TRAIL-mediated NK cell killing is critical for early cancer immunosurveillance and that tumors downregulate NKG2D ligands as an immune escape mechanism. Smyth has made significant contributions to combination immunotherapy, demonstrating that blockade of LAG-3 combined with anti-PD-1 produces synergistic anti-tumor effects and providing the preclinical rationale for relatlimab plus nivolumab combinations now approved for melanoma.

Share:

🧪Research Fields 研究领域

NK cell anti-tumor immunityNK细胞抗肿瘤免疫
ADCC and immune evasionADCC与免疫逃逸
checkpoint inhibitor combinations检查点抑制剂组合
LAG-3 immune evasionLAG-3免疫逃逸
NKG2D ligands tumor escapeNKG2D配体肿瘤逃逸

🎓Key Contributions 主要贡献

TRAIL-Mediated NK Cell Surveillance

Discovered that TRAIL-mediated killing by NK and NKT cells is essential for innate cancer immunosurveillance in multiple tumor models, establishing TRAIL pathway as a key effector mechanism of NK cell anti-tumor activity.

LAG-3 and PD-1 Combination Rationale

Provided preclinical evidence that co-blockade of LAG-3 and PD-1 produces synergistic tumor rejection beyond either single agent, forming the scientific basis for relatlimab plus nivolumab combination now approved for melanoma.

Representative Works 代表性著作

[1]

Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Contributes to Interferon Gamma-Dependent Natural Killer Cell Protection

Journal of Experimental Medicine (2001)

TRAIL role in NK cell tumor immunosurveillance.

[2]

Combined LAG-3 and PD-1 Blockade Promotes Antitumour Immunity

Journal of Experimental Medicine (2014)

Preclinical basis for LAG-3 plus PD-1 combination.

🏆Awards & Recognition 奖项与荣誉

🏆Australian Academy of Science David Syme Research Prize
🏆WEHI Burnet Prize
🏆AACR Cancer Immunology Research Award

📄Data Sources 数据来源

Institution

Last updated: 2026-01-15 | All information from publicly available academic sources

Related Experts 相关专家

Faisal Mahmood

Brigham and Women's Hospital; Harvard Medical School

Computational Pathology — Deep Learning for Whole-Slide Image Analysis and Tumor Microenvironment CharacterizationFoundation Models for Pathology — CONCH and TITAN Vision-Language Models for Oncology

Kun-Hsing Yu

Harvard Medical School; Brigham and Women's Hospital

Multimodal Oncology AI — Integrating Pathology Images, Genomics, Proteomics, and Clinical RecordsAI Pathology-Genomics Integration — Predicting Molecular Alterations from Histomorphology

Ziad Obermeyer

University of California, Berkeley; UC San Francisco

Algorithmic Bias in Healthcare AI — Racial Disparities in Predictive Risk ScoresPredictive Models for Cancer and Critical Illness — Machine Learning in Clinical Practice

Andrew H. Beck

PathAI; Harvard Medical School (formerly)

PathAI — Founding and Scientific Direction of AI-Powered Pathology PlatformDeep Learning for Pathology Biomarker Discovery — TILs, Fibrosis, and Tumor Architecture

关注 马克·史密斯 的研究动态

Follow Mark J. Smyth's research updates

留下邮箱，当我们发布与 Mark J. Smyth（QIMR Berghofer Medical Research Institute）相关的新研究或访谈时，我们会通知你。

我们不会泄露你的信息，也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment

Browse All ExpertsRead Research Insights